Jeffrey W. Tyner, Ph.D.
Affiliations: | Oregon Health and Science University, Portland, OR |
Area:
Cell Biology, Microbiology Biology, Molecular Biology, Public HealthGoogle:
"Jeffrey Tyner"Cross-listing: PHTree
Parents
Sign in to add mentor| Michael J. Holtzman | grad student | 2005 | Washington University | |
| (Role of CCL5 and EGFR in acute and chronic lung disease after respiratory viral infection.) | ||||
| Brian J. Druker | grad student | 2005-2010 | OHSU | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Modak RV, de Oliveira Rebola KG, McClatchy J, et al. (2024) Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Mohanty V, Baran N, Huang Y, et al. (2024) Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML. Biorxiv : the Preprint Server For Biology |
| Joshi SK, Pittsenbarger J, Kennedy VE, et al. (2023) The FLT3 mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. American Journal of Hematology |
| Eide CA, Kurtz SE, Kaempf A, et al. (2023) Clinical Correlates of Venetoclax-based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery |
| Yashar WM, Curtiss BM, Coleman DJ, et al. (2023) Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular Cancer Research : McR |
| Summers RJ, Jain J, Vasileiadi E, et al. (2022) Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers. 14 |
| Lachowiez CA, Long N, Saultz JN, et al. (2022) Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Advances |
| Rosenberg MW, Savage SL, Eide CA, et al. (2022) Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia. Cold Spring Harbor Molecular Case Studies. 8 |
| Gosline SJC, Tognon C, Nestor M, et al. (2022) Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML. Clinical Proteomics. 19: 30 |
| Bottomly D, Long N, Schultz AR, et al. (2022) Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell |